Erratum: Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design (PLoS Pathogens (2016) 12:8 (e1005815) DOI: 10.1371/journal.ppat.1005815);Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design

PLoS Pathogens

Volumn 12, Issue 8, 2016, Pages

  Jardine, Joseph G ^a,b   Sok, Devin ^a,c   Julien, Jean Philippe ^a,d   Briney, Bryan ^a   Sarkar, Anita ^a   Liang, Chi Hui ^a   Scherer, Erin A ^e   Henry Dunand, Carole J ^f   Adachi, Yumiko ^a,b   Diwanji, Devan ^a   Hsueh, Jessica ^a   Jones, Meaghan ^a,b   Kalyuzhniy, Oleksandr ^a,b   Kubitz, Michael ^a   Spencer, Skye ^a,b   Pauthner, Matthias ^a   Saye Francisco, Karen L ^a   Sesterhenn, Fabian ^a,h   Wilson, Patrick C ^f   Galloway, Denise M ^e   Stanfield, Robyn L ^a   Wilson, Ian A ^a   Burton, Dennis R ^a,g   Schief, William R ^a,b,g   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; CARDIOLIPIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ARTICLE; BIOINFORMATICS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG DESIGN; FLUOROMETRY; FREQUENCY ANALYSIS; GENE DELETION; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; MEMORY CELL; MOLECULAR DYNAMICS; NEXT GENERATION SEQUENCING; NONHUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SIZE EXCLUSION CHROMATOGRAPHY; VIRUS STRAIN; AMINO ACID SEQUENCE; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR MODEL; MUTATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; DRUG DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION;

EID: 84984802096     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005905     Document Type: Erratum

References (90)

1. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–9. doi: 10.1126/science.117874619729618; PubMed Central PMCID: PMC3335270.
2. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61. Epub 2010/07/10. doi: 10.1126/science.118765920616233; PubMed Central PMCID: PMC2965066.
3. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333(6049):1633–7. Epub 2011/07/19. doi: 10.1126/science.120722721764753; PubMed Central PMCID: PMC3351836.
4. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466–70. doi: 10.1038/nature1037321849977; PubMed Central PMCID: PMC3393110.
5. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. Journal of virology. 2011;85(19):9998–10009. doi: 10.1128/JVI.05045-1121795340; PubMed Central PMCID: PMC3196428.
6. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406–12. doi: 10.1038/nature1154423151583.
7. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496(7446):469–76. Epub 2013/04/05. nature12053 [pii] doi: 10.1038/nature1205323552890; PubMed Central PMCID: PMC3637846.
8. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498):55–62. doi: 10.1038/nature1303624590074; PubMed Central PMCID: PMC4395007.
9. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity. 2014;40(5):657–68. doi: 10.1016/j.immuni.2014.04.00924768347; PubMed Central PMCID: PMC4070425.
10. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014;515(7525):138–42. doi: 10.1038/nature1360125186731; PubMed Central PMCID: PMC4224615.
11. Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(49):17624–9. doi: 10.1073/pnas.141578911125422458; PubMed Central PMCID: PMC4267403.
12. Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, et al. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14Donors. Cell. 2015;161(6):1280–92. doi: 10.1016/j.cell.2015.05.00726004070.
13. Doria-Rose NA, Louder MK, Yang Z, O'Dell S, Nason M, Schmidt SD, et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. Journal of virology. 2012;86(6):3393–7. doi: 10.1128/JVI.06745-1122258252; PubMed Central PMCID: PMC3302320.
14. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(46):18921–5. Epub 2012/10/27. doi: 10.1073/pnas.121478510923100539; PubMed Central PMCID: PMC3503218.
15. Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. The Journal of experimental medicine. 2014;211(10):2061–74. doi: 10.1084/jem.2013249425155019; PubMed Central PMCID: PMC4172223.
16. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224–8. doi: 10.1038/nature1274424172905; PubMed Central PMCID: PMC4017780.
17. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013;503(7475):277–80. doi: 10.1038/nature1274624172896; PubMed Central PMCID: PMC4133787.
18. Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 2015;161(7):1505–15. doi: 10.1016/j.cell.2015.06.00326091035.
19. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L, Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS pathogens. 2011;7(1):e1001251. doi: 10.1371/journal.ppat.100125121249232; PubMed Central PMCID: PMC3020924.
20. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. Journal of virology. 2011;85(10):4828–40. doi: 10.1128/JVI.00198-1121389135; PubMed Central PMCID: PMC3126191.
21. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nature medicine. 2012;18(11):1688–92. doi: 10.1038/nm.298523086475; PubMed Central PMCID: PMC3494733.
22. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496(7446):469–76. Epub 2013/04/05. doi: 10.1038/nature1205323552890; PubMed Central PMCID: PMC3637846.
23. Burton DR, Stanfield RL, Wilson IA, Antibody vs. HIV in a clash of evolutionary titans. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(42):14943–8. doi: 10.1073/pnas.050512610216219699; PubMed Central PMCID: PMC1257708.
24. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(25):11483–8. doi: 10.1073/pnas.100460010720534513; PubMed Central PMCID: PMC2895122.
25. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811–7. Epub 2010/07/10. doi: 10.1126/science.119281920616231; PubMed Central PMCID: PMC2981354.
26. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153(1):126–38. doi: 10.1016/j.cell.2013.03.01823540694; PubMed Central PMCID: PMC3792590.
27. Mascola JR, Haynes BF, HIV-1 neutralizing antibodies: understanding nature's pathways. Immunological reviews. 2013;254(1):225–44. doi: 10.1111/imr.1207523772623; PubMed Central PMCID: PMC3738265.
28. Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe. 2014;16(3):304–13. doi: 10.1016/j.chom.2014.08.00625211073; PubMed Central PMCID: PMC4163498.
29. DeKosky BJ, Kojima T, Rodin A, Charab W, Ippolito GC, Ellington AD, et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nature medicine. 2015;21(1):86–91. doi: 10.1038/nm.374325501908.
30. Haynes BF, Kelsoe G, Harrison SC, Kepler TB, B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nature biotechnology. 2012;30(5):423–33. doi: 10.1038/nbt.219722565972; PubMed Central PMCID: PMC3512202.
31. Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell. 2014;158(3):481–91. doi: 10.1016/j.cell.2014.06.02225065977; PubMed Central PMCID: PMC4150607.
32. Zhou TQ, Georgiev I, Wu XL, Yang ZY, Dai KF, Finzi A, et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. Science. 2010;329(5993):811–7. doi: 10.1126/science.1192819WOS:000280809900043.
33. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK, et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science. 2011;333(6049):1633–7. doi: 10.1126/science.1207227WOS:000294900900044.
34. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, et al. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science. 2011;333(6049):1593–602. doi: 10.1126/science.1207532WOS:000294900900034.
35. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6(243):243ra88. doi: 10.1126/scitranslmed.300899224990883.
36. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 2014;88(21):12669–82. doi: 10.1128/JVI.02213-1425142607; PubMed Central PMCID: PMC4248941.
37. Kim AS, Leaman DP, Zwick MB, Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS pathogens. 2014;10(7):e1004271. doi: 10.1371/journal.ppat.100427125058619; PubMed Central PMCID: PMC4110039.
38. Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. Journal of virology. 2015;89(8):4201–13. doi: 10.1128/JVI.03608-1425631091; PubMed Central PMCID: PMC4442379.
39. Wu X, Zhang Z, Schramm CA, Joyce MG, Kwon YD, Zhou T, et al. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell. 2015;161(3):470–85. doi: 10.1016/j.cell.2015.03.00425865483; PubMed Central PMCID: PMC4706178.
40. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340(6133):711–6. Epub 2013/03/30. doi: 10.1126/science.123415023539181; PubMed Central PMCID: PMC3689846.
41. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. The Journal of experimental medicine. 2013;210(4):655–63. Epub 2013/03/27. doi: 10.1084/jem.2012282423530120; PubMed Central PMCID: PMC3620356.
42. McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, et al. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science. 2014;346(6215):1380–3. doi: 10.1126/science.125920625504724; PubMed Central PMCID: PMC4290850.
43. Jardine JG, Kulp DW, Havenar-Daughton C, Sarkar A, Briney B, Sok D, et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science. 2016;351(6280):1458–63. doi: 10.1126/science.aad919527013733.
44. Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science. 2015;349(6244):156–61. Epub Jun 18. doi: 10.1126/science.aac589426089355.
45. Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, et al. Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. Science. 2011;334(6060):1289–93. doi: 10.1126/science.1213782WOS:000297553600054.
46. West AP, Jr.Diskin R, Nussenzweig MC, Bjorkman PJ, Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(30):E2083–90. doi: 10.1073/pnas.120898410922745174; PubMed Central PMCID: PMC3409792.
47. Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather DN, Marcovecchio PM, et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. The Journal of experimental medicine. 2013;210(6):1235–49. doi: 10.1084/jem.2013022123712429; PubMed Central PMCID: PMC3674693.
48. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013;342(6165):1484–90. Epub 2013/11/02. doi: 10.1126/science.124562724179160; PubMed Central PMCID: PMC3954647.
49. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity. 2013;39(2):245–58. doi: 10.1016/j.immuni.2013.04.01223911655; PubMed Central PMCID: PMC3985390.
50. Georgiev IS, Rudicell RS, Saunders KO, Shi W, Kirys T, McKee K, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. Journal of immunology. 2014;192(3):1100–6. doi: 10.4049/jimmunol.130251524391217; PubMed Central PMCID: PMC4140862.
51. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. Journal of virology. 2012;86(21):11521–32. doi: 10.1128/JVI.01023-1222896626; PubMed Central PMCID: PMC3486290.
52. Lavinder JJ, Wine Y, Giesecke C, Ippolito GC, Horton AP, Lungu OI, et al. Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(6):2259–64. doi: 10.1073/pnas.131779311124469811; PubMed Central PMCID: PMC3926051.
53. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38(1):176–86. doi: 10.1016/j.immuni.2012.11.01123313589; PubMed Central PMCID: PMC3569735.
54. Scherer EM, Smith RA, Simonich CA, Niyonzima N, Carter JJ, Galloway DA, Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS pathogens. 2014;10(10):e1004461. doi: 10.1371/journal.ppat.100446125330199; PubMed Central PMCID: PMC4199765.
55. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. The Journal of experimental medicine. 2011;208(1):181–93. doi: 10.1084/jem.2010135221220454; PubMed Central PMCID: PMC3023136.
56. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H, Autoreactivity in human IgG+ memory B cells. Immunity. 2007;26(2):205–13. doi: 10.1016/j.immuni.2007.01.00917306569; PubMed Central PMCID: PMC1839941.
57. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of virology. 2005;79(16):10108–25. doi: 10.1128/JVI.79.16.10108–10125.200516051804; PubMed Central PMCID: PMC1182643.
58. Richman DD, Wrin T, Little SJ, Petropoulos CJ, Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(7):4144–9. doi: 10.1073/pnas.063053010012644702; PubMed Central PMCID: PMC153062.
59. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011;333(6049):1593–602. Epub 2011/08/13. doi: 10.1126/science.120753221835983.
60. Diskin R, Scheid JF, Marcovecchio PM, West AP, Jr.Klein F, Gao H, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 2011;334(6060):1289–93. Epub 2011/10/29. science.1213782 [pii] doi: 10.1126/science.121378222033520; PubMed Central PMCID: PMC3232316.
61. Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26(10):663–70. doi: 10.1093/protein/gzt04724046438.
62. Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. mAbs. 2015;7(4):770–7. doi: 10.1080/19420862.2015.104350326047159; PubMed Central PMCID: PMC4622737.
63. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342(6165):1477–83. Epub 2013/11/02. doi: 10.1126/science.124562524179159; PubMed Central PMCID: PMC3886632.
64. Do Kwon Y, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol. 2015;22(7):522–31. doi: 10.1038/nsmb.305126098315.
65. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science. 2014;346(6210):759–63. doi: 10.1126/science.125442625298114; PubMed Central PMCID: PMC4304640.
66. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med. 2014;6(236):236ra63. doi: 10.1126/scitranslmed.300810424828077; PubMed Central PMCID: PMC4095976.
67. Schief WR, Ban YE, Stamatatos L, Challenges for structure-based HIV vaccine design. Current opinion in HIV and AIDS. 2009;4(5):431–40. Epub 2010/01/06. doi: 10.1097/COH.0b013e32832e618420048708.
68. Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, Menis S, et al. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS pathogens. 2015;11(5):e1004932. doi: 10.1371/journal.ppat.100493226023780; PubMed Central PMCID: PMC4449185.
69. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(31):13800–5. doi: 10.1073/pnas.100649810720643940; PubMed Central PMCID: PMC2922250.
70. McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun. 2016;7:10618. doi: 10.1038/ncomms1061826907590.
71. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science. 2015;349(6244):aac4223. doi: 10.1126/science.aac422326089353; PubMed Central PMCID: PMC4498988.
72. Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD, PANDAseq: paired-end assembler for illumina sequences. BMC Bioinformatics. 2012;13:31. doi: 10.1186/1471-2105-13-3122333067; PubMed Central PMCID: PMC3471323.
73. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37(Database issue):D1006–12. doi: 10.1093/nar/gkn83818978023; PubMed Central PMCID: PMC2686541.
74. Joshi N, Fass J. Sickle: A sliding-window, adaptive, quality-based trimming tool for FastQ files (Version 1.33) [Software]. Available at https://githubcom/najoshi/sickle. 2011.
75. Brochet X, Lefranc MP, Giudicelli V, IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36(Web Server issue):W503–8. doi: 10.1093/nar/gkn31618503082; PubMed Central PMCID: PMC2447746.
76. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802. doi: 10.1001/jama.2013.162523632723.
77. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4(3):372–84. doi: 10.1038/nprot.2009.319247287; PubMed Central PMCID: PMC2750034.
78. Briney BS, Willis JR, Crowe JE, JrHuman peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One. 2012;7(5):e36750. doi: 10.1371/journal.pone.003675022590602; PubMed Central PMCID: PMC3348910.
79. Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, Katpally U, et al. Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. The Journal of biological chemistry. 2012;287(29):24239–54. Epub 2012/05/31. doi: 10.1074/jbc.M112.37189822645128; PubMed Central PMCID: PMC3397850.
80. Kabsch W, Xds. Acta crystallographica Section D, Biological crystallography. 2010;66(Pt 2):125–32. Epub 2010/02/04. doi: 10.1107/S090744490904733720124692; PubMed Central PMCID: PMC2815665.
81. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ, Phaser crystallographic software. Journal of applied crystallography. 2007;40(Pt 4):658–74. Epub 2007/08/01. doi: 10.1107/S002188980702120619461840; PubMed Central PMCID: PMC2483472.
82. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica Section D, Biological crystallography. 2010;66(Pt 2):213–21. Epub 2010/02/04. doi: 10.1107/S090744490905292520124702; PubMed Central PMCID: PMC2815670.
83. Emsley P, Cowtan K, Coot: model-building tools for molecular graphics. Acta crystallographica Section D, Biological crystallography. 2004;60(Pt 12 Pt 1):2126–32. Epub 2004/12/02. doi: 10.1107/S090744490401915815572765.
84. Sarkar A, Drouillard S, Rivet A, Perez S, Databases of Conformations and NMR Structures of Glycan Determinants. Glycobiology. 2015;25(12):1480–90. doi: 10.1093/glycob/cwv05426240168.
85. Kirschner KN, Yongye AB, Tschampel SM, Gonzalez-Outeirino J, Daniels CR, Foley BL, et al. GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem. 2008;29(4):622–55. doi: 10.1002/jcc.2082017849372.
86. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C, Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins: Struct, Funct, Bioinf. 2006;65(3):712–25. doi: 10.1002/prot.21123
87. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, et al. Amber 12: University of California, San Francisco; 2012.
88. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79(2):926–35. doi:http://dx.doi.org/10.1063/1.445869.
89. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, et al. The Amber biomolecular simulation programs. J Comp Chem. 2005;26(16):1668–88. doi: 10.1002/jcc.20290
90. Krissinel E, Henrick K, Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372(3):774–97. doi: 10.1016/j.jmb.2007.05.02217681537.